Mayflower Financial Advisors’s GSK GSK Stock Holding History

Mayflower Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$228K	Buy	4,342 +582	+15%	+$30.8K	0.02%	446
2026 Q1	$208K	Buy	+3,760	New	+$204K	0.03%	428
2023 Q4	–	Sell	-5,635	Closed	-$204K	–	349
2023 Q3	$204K	Buy	+5,635	New	+$200K	0.03%	317
2022 Q3	–	Sell	-5,395	Closed	-$294K	–	346
2022 Q2	$294K	Buy	5,395 +25	+0.5%	+$1.38K	0.05%	251
2022 Q1	$292K	Buy	5,370 +36	+0.7%	+$1.96K	0.04%	273
2021 Q4	$294K	Buy	5,334 +222	+4%	+$11.5K	0.04%	271
2021 Q3	$250K	Buy	5,112 +34	+0.7%	+$1.71K	0.03%	284
2021 Q2	$253K	Sell	5,078 -699	-12%	-$33.6K	0.03%	269
2021 Q1	$258K	Sell	5,777 -352	-6%	-$16K	0.04%	250
2020 Q4	$282K	Buy	+6,129	New	+$282K	0.05%	215

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mayflower Financial Advisors's GSK Position: Q2 2026 in Review

Mayflower Financial Advisors increased its GSK (GSK) stake by 15% in Q2 2026, buying an estimated $30.8K and bringing the position to 4,342 shares worth $228K. The position accounts for 0.02% of the portfolio, ranked #446.

Mayflower Financial Advisors first reported a position in GSK in Q4 2020 and has held it in 10 quarters since. The position peaked at $294K in Q2 2022. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Mayflower Financial Advisors held 4,342 shares of GSK worth $228K as of Q2 2026.
Mayflower Financial Advisors bought 582 GSK shares in Q2 2026, an estimated $30.8K.
GSK made up 0.02% of Mayflower Financial Advisors's portfolio in Q2 2026, its #446 holding.
Mayflower Financial Advisors first reported a position in GSK in Q4 2020 and has held it in 10 quarters since.
Mayflower Financial Advisors's GSK position peaked at $294K in Q2 2022.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Mayflower Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.